Hinge Health Inc. (NYSE:HNGE) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Hinge Health Inc. (NYSE:HNGE) have been assigned a consensus recommendation of “Moderate Buy” from the twenty research firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, sixteen have given a buy rating and two have assigned a strong buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $67.5333.

HNGE has been the subject of a number of recent analyst reports. Royal Bank Of Canada increased their price target on Hinge Health from $55.00 to $65.00 and gave the company an “outperform” rating in a research report on Wednesday, May 6th. Evercore reiterated an “outperform” rating and issued a $45.00 price target on shares of Hinge Health in a research report on Wednesday, April 8th. Raymond James Financial reiterated an “outperform” rating and issued a $70.00 price target on shares of Hinge Health in a research report on Wednesday, May 6th. Citizens Jmp increased their price objective on Hinge Health from $65.00 to $80.00 and gave the stock a “market outperform” rating in a research note on Wednesday, May 6th. Finally, Citigroup reissued an “outperform” rating on shares of Hinge Health in a research note on Wednesday, May 6th.

Insider Transactions at Hinge Health

In related news, Chairman Gabriel M.I. Mecklenburg sold 50,000 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $65.54, for a total value of $3,277,000.00. Following the transaction, the chairman directly owned 50,000 shares of the company’s stock, valued at approximately $3,277,000. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Antonio Perez sold 45,456 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $55.05, for a total value of $2,502,352.80. Following the completion of the transaction, the chief executive officer directly owned 35,470 shares in the company, valued at $1,952,623.50. The trade was a 56.17% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 554,600 shares of company stock valued at $29,859,068 over the last 90 days. Company insiders own 18.92% of the company’s stock.

Institutional Trading of Hinge Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Janney Montgomery Scott LLC grew its holdings in shares of Hinge Health by 3.3% during the 1st quarter. Janney Montgomery Scott LLC now owns 9,400 shares of the company’s stock worth $362,000 after purchasing an additional 300 shares in the last quarter. Wells Fargo & Company MN grew its holdings in shares of Hinge Health by 160.0% during the 4th quarter. Wells Fargo & Company MN now owns 546 shares of the company’s stock worth $25,000 after purchasing an additional 336 shares in the last quarter. Lazard Asset Management LLC grew its holdings in shares of Hinge Health by 0.6% during the 1st quarter. Lazard Asset Management LLC now owns 63,705 shares of the company’s stock worth $2,456,000 after purchasing an additional 386 shares in the last quarter. First Horizon Corp grew its holdings in shares of Hinge Health by 163.9% during the 4th quarter. First Horizon Corp now owns 855 shares of the company’s stock worth $40,000 after purchasing an additional 531 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in shares of Hinge Health during the 4th quarter worth approximately $26,000.

Hinge Health Stock Performance

NYSE:HNGE opened at $63.48 on Monday. Hinge Health has a 1 year low of $30.08 and a 1 year high of $66.55. The stock has a market cap of $4.91 billion and a price-to-earnings ratio of -5.14. The business has a fifty day moving average of $47.93 and a 200-day moving average of $45.34.

Hinge Health (NYSE:HNGE) last announced its earnings results on Tuesday, May 5th. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.33. Hinge Health had a negative return on equity of 310.62% and a negative net margin of 78.95%.The business had revenue of $182.31 million during the quarter. During the same period in the prior year, the business earned $1.30 EPS. The company’s quarterly revenue was up 47.2% compared to the same quarter last year. On average, equities research analysts predict that Hinge Health will post 1.21 EPS for the current year.

Key Headlines Impacting Hinge Health

Here are the key news stories impacting Hinge Health this week:

• Positive Sentiment: Canaccord Genuity raised its price target on Hinge Health to $65 from $63 and reiterated a buy rating, reinforcing a constructive analyst view on the stock. Article Title
• Positive Sentiment: Other recent commentary also stayed upbeat, including technical coverage pointing to a “golden cross,” which can attract momentum investors. Article Title
• Positive Sentiment: Hinge Health’s last earnings report beat estimates, with revenue up 47.2% year over year, supporting the view that the business is still growing rapidly. Article Title
• Neutral Sentiment: One article highlighted Hinge Health as a promising mid-cap healthcare name, but it did not include a new catalyst beyond a generally favorable long-term investment case. Article Title
• Negative Sentiment: Chairman Gabriel M.I. Mecklenburg disclosed another large insider sale of 50,000 shares at $65.54, adding to a series of recent sales and potentially creating some overhang for sentiment. Article Title

About Hinge Health

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.